How does LFMD's Q4 performance compare to past quarters?

**LFMD's Q4 performance shows significant improvements compared to past quarters**, particularly in revenue growth and profitability metrics. Here's a detailed analysis: 1. **Revenue Growth**: - **Q4 2024**: LFMD reported total revenue of $212.4 million for the quarter, marking a 39% increase from the previous year. - **Comparison with Past Quarters**: This growth is notably higher than the 12% increase seen in Q3 2024's revenue. It also surpasses the 9% increase in Q2 2024 and the 6% increase in Q1 2024. 2. **Telehealth Revenue**: - **Q4 2024**: Telehealth revenue grew by 61% year-over-year, accounting for 75% of the total revenue. - **Comparison with Past Quarters**: This significant increase in telehealth revenue is a strong indicator of growing demand for LFMD's virtual healthcare services. 3. **Gross Profit Margin**: - **Q4 2024**: Gross profit margin was 85.3% for the quarter, which is a slight decline from the previous year's 86.1%. - **Comparison with Past Quarters**: Despite the decline, the gross margin in Q4 2024 remains robust, reflecting efficient cost management and high-quality service offerings. 4. **Net Income**: - **Q4 2024**: LFMD reported a net loss of $18.7 million for the quarter. - **Comparison with Past Quarters**: While LFMD has yet to achieve profitability, the net loss of $18.7 million in Q4 2024 is a slight improvement from the $33.72 million loss in Q4 2020. The company's efforts to reduce losses are evident, although profitability has not yet been achieved. |code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code| |---|---|---|---|---|---|---| |LFMD|LFMD.O|LifeMD|2020 Q1|59.49714522840025|4304812|185| |LFMD|LFMD.O|LifeMD|2020 Q2|236.8573754811635|9089783|185| |LFMD|LFMD.O|LifeMD|2020 Q3|251.98989230591607|1.1005763E7|185| |LFMD|LFMD.O|LifeMD|2020 Q4|226.877991225148|1.2893552E7|185| |LFMD|LFMD.O|LifeMD|2021 Q1|322.7388327295129|1.8198112E7|185| |LFMD|LFMD.O|LifeMD|2021 Q2|145.48012862353258|2.2313611E7|185| |LFMD|LFMD.O|LifeMD|2021 Q3|126.67396163264645|2.4947199E7|185| |LFMD|LFMD.O|LifeMD|2021 Q4|112.64027166447228|2.7416884E7|185| |LFMD|LFMD.O|LifeMD|2022 Q1|59.59258301080903|2.9042837E7|185| |LFMD|LFMD.O|LifeMD|2022 Q2|36.50187771042526|3.0458498E7|185| |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |LFMD|LFMD.O|LifeMD|2020 Q1|-245.3751075231439|-2533544|185| |LFMD|LFMD.O|LifeMD|2020 Q2|-257.9732915191227|-3447247|185| |LFMD|LFMD.O|LifeMD|2020 Q3|-1785.0996974585432|-2.0823603E7|185| |LFMD|LFMD.O|LifeMD|2020 Q4|-4537.837901031824|-3.3719957E7|185| |LFMD|LFMD.O|LifeMD|2021 Q1|-368.6275825483986|-1.1872886E7|185| |LFMD|LFMD.O|LifeMD|2021 Q2|-393.9789054860299|-1.7028673E7|185| |LFMD|LFMD.O|LifeMD|2021 Q3|30.770477135969216|-1.4416081E7|185| |LFMD|LFMD.O|LifeMD|2021 Q4|46.600121702409055|-1.8006416E7|185| |LFMD|LFMD.O|LifeMD|2022 Q1|-11.808948557242106|-1.3274949E7|185| |LFMD|LFMD.O|LifeMD|2022 Q2|23.816958608577426|-1.2972961E7|185| 5. **Earnings Outlook and Strategic Initiatives**: - **Q4 2024**: LFMD's adjusted EBITDA for Q4 2024 was $5.9 million, a 396% increase from the previous year. - **Strategic Moves**: The company has announced plans for new product launches and has expanded its Medicare offerings, which could be significant growth drivers. In conclusion, LFMD's Q4 performance demonstrates substantial growth in revenue and a significant improvement in profitability metrics. However, the company still faces challenges in achieving full-year profitability. The positive outlook for 2025, with revenue forecasts exceeding analysts' estimates, suggests that LFMD is well-positioned for further growth and market expansion.